DZDan Zhou

Dan Zhou

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Dan Zhou has a total of 7 co-authors. Here are the top co-authors by number of shared publications:

  • Li Yang

    Department of Internal Medicine, Brody School of Medicine, East Carolina University, Greenville, NC 27834, USA

    3 shared publications
  • LeYu Zhou

    Department of Gastroenterology and Hepatology and Laboratory of Gastrointestinal Cancer and Liver Disease, West China Hospital Sichuan University Chengdu Sichuan Province China

    2 shared publications
  • Yi Shen

    Department of Gastroenterology and Hepatology, and Laboratory of Gastrointestinal Cancer and Liver Disease West China Hospital, Sichuan University Chengdu Sichuan Province China

    2 shared publications
  • Yongqi Dong

    Department of Gastroenterology and Hepatology, and Laboratory of Gastrointestinal Cancer and Liver Disease West China Hospital, Sichuan University Chengdu Sichuan Province China

    2 shared publications
  • Kunyi Ba

    Department of Gastroenterology and Hepatology, and Laboratory of Gastrointestinal Cancer and Liver Disease, West China Hospital, Sichuan University, Chengdu, China, scu.edu.cn

    1 shared publication
  • Tingting Jia

    Department of Gastroenterology and Hepatology, and Laboratory of Gastrointestinal Cancer and Liver Disease, West China Hospital, Sichuan University, Chengdu, China, scu.edu.cn

    1 shared publication

Latest Publications

  • Reply to ‘Biopsy Before Autoimmune Hepatitis Withdrawal: The Estimand Matters’

    by Yongqi Dong, Dan Zhou, LeYu Zhou, Li Yang, Yi Shen

  • Relapse After Treatment Withdrawal in Autoimmune Hepatitis: Biopsy‐Guided Versus Clinically Guided Strategies—A Meta‐Analysis

    by Yongqi Dong, Dan Zhou, Leyu Zhou, Li Yang, Yi Shen

    Long‐term immunosuppression in autoimmune hepatitis (AIH) carries substantial side effects, making treatment withdrawal an important consideration after sustained biochemical remission. Whether biopsy‐guided withdrawal based on histological assessment reduces relapse compared with clinically guided withdrawal remains uncertain. We conducted a systematic review and meta‐analysis to compare relapse rates between these two strategies. This meta‐analysis followed PRISMA 2020. PubMed, Embase, Web of Science, Scopus and the Cochrane Library were searched from inception to identify studies reporting relapse after treatment withdrawal in AIH using biopsy‐guided or clinically guided strategies. Pooled relapse rates were estimated using random‐effects models of transformed proportions. Prespecified subgroup, sensitivity and meta‐regression analyses evaluated the impact of relapse definitions, histological stringency and follow‐up duration. Twelve studies (518 patients) were included. The pooled relapse rate after treatment withdrawal was 51.1%. Relapse rates were not significantly different between biopsy‐guided (48.3%) and clinically guided withdrawal (56.3%; p = 0.604). Studies defining relapse by transaminase elevation alone reported higher relapse rates than those incorporating IgG elevation. Within biopsy‐guided cohorts, stricter histological remission thresholds were associated with lower relapse rates and reduced heterogeneity.Relapse after treatment withdrawal in AIH remained common and did not differ significantly between biopsy‐guided and clinically guided strategies. In the context of existing guideline recommendations, current evidence does not clearly support routine prewithdrawal liver biopsy in all patients with sustained biochemical remission. Trial Registration: PROSPERO registration number: 4202511295


  • Open Access

    Recompensation of Liver Cirrhosis: Definition, Mechanism, Etiological Differences, Prognosis, and Challenges

    by Dan Zhou, Kunyi Ba, Tingting Jia, Yi Shen, Li Yang

    The progression from compensated to decompensated cirrhosis has historically been considered irreversible. However, accumulating clinical evidence has given rise to the concept of “recompensation,” which posits that a subset of patients with decompensated cirrhosis may regain a compensated state following successful etiological control, leading to a markedly improved prognosis. This review synthesizes current evidence on cirrhosis recompensation, examining its definition, mechanisms, and etiological specificities, while also addressing the prognosis and persistent challenges in this patient population. Further research is needed to refine the definition of recompensation and elucidate the underlying mechanisms and determinants.